T2 Biosystems company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

t2biosystems.com

Founded Year

2006

Stage

IPO | IPO

Total Raised

$96.24M

Date of IPO

8/7/2014

Market Cap

0.03B

Stock Price

0.17

About T2 Biosystems

T2 Biosystems develops in-vitro diagnostics. It specializes in products targeting sepsis, hemostasis, bacteria and Lyme disease.

T2 Biosystems Headquarter Location

91 Hartwell Avenue

Lexington, Massachusetts, 02421,

United States

781-457-1200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing T2 Biosystems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

T2 Biosystems is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

12,017 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

H

Health IT

7,900 items

T2 Biosystems Patents

T2 Biosystems has filed 70 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Biotechnology
  • Analytical chemistry
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/21/2016

5/10/2022

Bacterial diseases, Rickettsioses, Molecular biology, Rickettsiaceae, Bacterium-related cutaneous conditions

Grant

Application Date

1/21/2016

Grant Date

5/10/2022

Title

Related Topics

Bacterial diseases, Rickettsioses, Molecular biology, Rickettsiaceae, Bacterium-related cutaneous conditions

Status

Grant

Latest T2 Biosystems News

T2 Biosystems to Appear on the Benzinga All Access Show on June 17, 2022

Jun 15, 2022

Lexington, Massachusetts, UNITED STATES LEXINGTON, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to appear on the Benzinga All Access show on Friday, June 17, 2022. Management is scheduled to be interviewed that day at 9:40am ET. A link to the live and recorded YouTube broadcast will be available on the Events & Presentations section of the T2 Biosystems’ Investor Relations website http://investors.t2biosystems.com . About T2 Biosystems T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the T2Biothreat™ Panel, the T2Cauris™ Panel, and T2Lyme™ Panel, as well as next-generation products for the detection of bacterial and fungal pathogens and associated antimicrobial resistance markers. Investor Contact:

T2 Biosystems Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

T2 Biosystems Rank

  • When was T2 Biosystems founded?

    T2 Biosystems was founded in 2006.

  • Where is T2 Biosystems's headquarters?

    T2 Biosystems's headquarters is located at 91 Hartwell Avenue, Lexington.

  • What is T2 Biosystems's latest funding round?

    T2 Biosystems's latest funding round is IPO.

  • How much did T2 Biosystems raise?

    T2 Biosystems raised a total of $96.24M.

  • Who are the investors of T2 Biosystems?

    Investors of T2 Biosystems include Flybridge Capital Partners, Polaris Partners, Flagship Pioneering, Partners Innovation Fund, Physic Ventures and 11 more.

  • Who are T2 Biosystems's competitors?

    Competitors of T2 Biosystems include Akonni Biosystems, iMMCO Diagnostics, Esaote, Advanced Cell Diagnostics, LipoScience and 13 more.

You May Also Like

G
Gold Standard Diagnostics

Gold Standard Diagnostics (GSD) provides diagnostic solutions that improve lab efficiency and minimize overall costs. Through an extensive product menu, automated instrument platforms, and outstanding customer service, GSD solves real laboratory problems. The result is a seamless laboratory experience achieved through an integrated approach.

S
SENTINEL CH SpA

Sentinel Diagnostics is an Italian company with a long and well established background in the development and production of diagnostic kits destined for use in medical analysis laboratories, hospitals, clinics and private health care structures.

S
SPOC

SPOC is a provider of a diagnostic medical device that identifies the specific myofacial (muscle) trigger points that SPOC says are often overlooked by conventional diagnosis which can cause neck and back pain. This device together with the patented clinical methodology developed by Dr. Norman Marcus, SPOC's chief medical officer and engaged in pain management, aim to provide a complete diagnostic package for accurate and precise identification of muscle pain.

C
Cellatope Corporation

Cellatope is a cell analysis company that is developing research and diagnostic products and services in the field of autoimmune and inflammatory disease, with an initial focus on lupus and transplant medicine.

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

C
Clinical Laboratory Partners

Clinical Laboratory Partners is a provider of clinical diagnostic testing services for healthcare providers, both hospitals and private practices, effectively competing in local markets against a range of national and other local clinical diagnostic laboratories.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.